Hydreight Technologies to Present at Maxim Group’s 2025 Virtual Tech Conference & the CEM Bermuda Capital Event

In This Article:

Hydreight Technologies Inc.
Hydreight Technologies Inc.

VANCOUVER, British Columbia and LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth services across the United States, today announced that Shane Madden, CEO of Hydreight, will be presenting at the following investor conferences in June 2025:

2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow

Hosted by: Maxim Group LLC
Date: June 3–5, 2025
Presentation Time: Tuesday, June 3rd at 12:30 PM PT / 3:30 PM ET
Location: Virtual (M-Vest Platform)
Registration: Click here to attend

Maxim’s 2025 Virtual Tech Conference explores how emerging growth companies are leveraging technologies such as AI and telehealth to shape the future of healthcare and other industries. Hydreight’s presentation will highlight its national healthcare infrastructure, proprietary technology platform, and strategy to scale its direct-to-consumer and pharmacy verticals.

CEM Bermuda Capital Event

Date: June 6–8, 2025
Location: Bermuda
Conference Info: cem.ca/conference/bermuda-capital-event-2025

Hydreight will participate in one-on-one meetings with institutional and high-net-worth investors throughout the conference.

Recent Company Highlights

Hydreight recently reported audited financial results for the fiscal year ended December 31, 2024, achieving several financial and operational milestones:

  • FY2024 Adjusted Revenue¹: $22.32 million CAD (↑31% YoY)

  • GAAP Revenue: $16.04 million CAD (↑39% YoY)

  • Adjusted EBITDA¹: +$490,000 CAD (vs. -$1.38 million in FY2023)

  • Cash Flow from Operations: +$857,000 CAD

  • Current Cash Position: $6.8 million CAD

  • Licenses Sold: Over 400 D2C brands across all 50 states

  • Network Scale: More than 3,000 nurses and 200 physicians

Please see SEDAR+ for the Company’s audited annual consolidated financial statements and MD&A for the year ends.

In 2024, Hydreight expanded its offerings to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications. The Company also secured strategic partnerships with national health franchises and clinical experts, including The DRIPBaR and Dr. Franklin Joseph.

FY2024 Earnings Call

Hydreight hosted its 2024 year-end earnings call on May 6, 2025, where CEO Shane Madden and COO Vahid Shababi reviewed the Company’s financial performance and strategic roadmap. The call covered highlights including margin expansion, platform scale, and strong early momentum from its D2C healthcare initiative, VSDHOne.